It was learned last week that a follow-up deal to BioPharma Royalty Trust is in the works and could emerge in the next several weeks.

Unlike the first BioPharma, which was tied to the royalty of HIV drug Zerit, the pending deal will tap the cash flow associated with a pool of patents, allowing diversification to improve the structure.

Subscribe Now

Access to a full range of industry content, analysis and expert commentary.

30-Day Free Trial

No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.